Neutralization of HIV-1: a paradox of humoral proportions
- PMID: 1712328
- DOI: 10.1096/fasebj.5.10.1712328
Neutralization of HIV-1: a paradox of humoral proportions
Abstract
The production of immunoglobulin capable of neutralizing the infectivity of a virus represents one of the most remarkable molecular accomplishments of the host's available immune defenses. It should be no surprise that a virus that has existed in the parenchyma of the immune system has evolved as an equally dynamic molecule (i.e., viral envelope) for survival. Neutralizing immunoglobulin (Ig) can best serve the host under conditions where the invading pathogen requires a well-defined cell-free state for establishing an infection or transmission. Evidence for a controlling and therefore protective role of neutralizing Ig against lentiviruses has been defined in natural and experimental infections with equine infectious anemia virus of ungulate members in the family equidae. Rapid replication of the virus immediately after infection and its release in a cell-free state leads to the production of neutralizing Ig and subsequent control of the primary viremia. A similar cause-effect relationship exists in humans between the high-titered viremia, observed shortly after HIV-1 infection, and the subsequent production of neutralizing Ig. Partially controlling this acute stage of viral replication by neutralizing Ig and thus preventing an otherwise acute form of immunosuppression or immune complex disease may be viewed paradoxically as a survival property of the virus. Immunologically mediated control, in a Darwinian sense, selects for viruses that have optimized the parameters of longevity and transmission from host to host. This paradox of neutralization in HIV-1 infection appears to be mediated by the convergence of structural and functional roles of the third variable domain (V3) of the external envelope glycoprotein. During infection or envelope-based vaccination, antibody to this cross-reactive, immuno-dominant epitope dominates the antigenic repertoire. Once this occurs, the host is less able to respond to emerging viruses containing closely related V3 structures. Thus a relatively restricted clonal-dominance of the neutralization response results. The V3 domain, apparently in concert with the rest of the molecule, provides an epitope that can tolerate and utilize its conformational flexibility to allow immune escape while maintaining its functional role in infectivity. Sixteen other putative epitopes have been described as being involved in the induction of neutralizing Ig. Currently the biologically functional role of neutralizing Ig to these other epitopes are complicated by a prior lack of knowledge and appreciation of the in vitro variables affecting their measurements.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.Curr Top Microbiol Immunol. 1994;188:185-219. doi: 10.1007/978-3-642-78536-8_11. Curr Top Microbiol Immunol. 1994. PMID: 7523031 Review.
-
HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.J Virol. 2017 Oct 13;91(21):e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1. J Virol. 2017. PMID: 28835491 Free PMC article.
-
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15. J Virol. 2016. PMID: 26763999 Free PMC article.
-
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.PLoS Pathog. 2018 Jan 25;14(1):e1006825. doi: 10.1371/journal.ppat.1006825. eCollection 2018 Jan. PLoS Pathog. 2018. PMID: 29370298 Free PMC article.
-
Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression.Int Rev Immunol. 1992;8(1):65-81. doi: 10.3109/08830189209056642. Int Rev Immunol. 1992. PMID: 1374113 Review.
Cited by
-
Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.J Virol. 1994 Feb;68(2):974-8. doi: 10.1128/JVI.68.2.974-978.1994. J Virol. 1994. PMID: 7507188 Free PMC article.
-
Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains.J Virol. 2005 Oct;79(19):12311-20. doi: 10.1128/JVI.79.19.12311-12320.2005. J Virol. 2005. PMID: 16160158 Free PMC article.
-
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.J Virol. 1994 Aug;68(8):4821-8. doi: 10.1128/JVI.68.8.4821-4828.1994. J Virol. 1994. PMID: 7518527 Free PMC article.
-
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.J Virol. 1995 Oct;69(10):6239-48. doi: 10.1128/JVI.69.10.6239-6248.1995. J Virol. 1995. PMID: 7666524 Free PMC article.
-
Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.J Virol. 1993 Mar;67(3):1693-7. doi: 10.1128/JVI.67.3.1693-1697.1993. J Virol. 1993. PMID: 7679751 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources